Krystal Biotech, Inc.

KRYS

$371.47

+0.61%

N/A+$2.24

Healthcare

Biotechnology

NASDAQ

Active Trading

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United ...

Key Metrics of KRYS

Snapshot

Latest / TTM · 6 periods

Market Cap

$10.95B

ROCE

14.4%

EV / EBITDA

48.22x

+1.3% YoY

FCF Yield

2.4%

-0.3% YoY

Cash Conversion Cycle

600.2d

Current Ratio

8.32

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$1.55B	$2.02B	$3.37B	$4.48B	$7.14B	$10.95B
Enterprise ValueCompany value including debt and cash adjustments.	$1.22B	$1.87B	$3.02B	$4.14B	$6.65B	$10.53B
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	59.54x	14.26x	17.09x	23.91x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-18.41x	-15.98x	-33.06x	37.68x	33.92x	48.22x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	5.03	1.31	3.84	-3.07	-2.48	-1.92

Returns + ROCE gauge

ROCE latest

14.4%

Prev year 13.1%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-11.7%	-26.8%	1.4%	9.4%	16.8%	19.3%
ROAProfit generated from total assets.	-11.1%	-25.1%	1.3%	8.4%	15.4%	16.1%
ROICReturn generated on invested operating capital.	-12.7%	-22.9%	-11.4%	12.0%	19.0%	20.8%
ROCEOperating return on long-term capital used.	-11.4%	-27.4%	-14.0%	6.9%	13.1%	14.4%
Earnings YieldEarnings as a percentage of market value.	-4.5%	-6.9%	0.3%	2.0%	2.9%	2.2%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-114.78M	$-153.55M	$-100.60M	$119.18M	$188.91M	$257.78M
FCFECash flow available to equity holders after debt flows.	$-116.27M	$-153.55M	$-100.60M	$119.18M	$188.91M	$257.78M
FCF YieldFree cash flow divided by market capitalization.	-7.5%	-7.6%	-3.0%	2.7%	2.6%	2.4%
Income QualityHow well accounting earnings are backed by cash flow.	0.69	0.72	-8.12	1.38	0.98	1.13
Capex / OCFShare of operating cash flow spent on capital expenditures.	-142.6%	-52.7%	-13.3%	3.4%	5.9%	5.3%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	302.7d	131.6d	119.5d	114.9d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	824.0d	482.3d	513.4d	566.7d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	218.1d	90.7d	41.1d	81.4d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	1126.7d	613.9d	633.0d	681.6d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	908.6d	523.2d	591.9d	600.2d

Snapshot

Latest / TTM: —

Market Cap

$10.95B

ROE

19.3%

FCF Yield

2.4%

Current Ratio

8.32

Upstream

Krystal Biotech Internal Manufacturing (Pittsburgh Facility)NASDAQ:KRYS Thermo Fisher Scientific Inc.NYSE:TMO Danaher Corporation (Cytiva)NYSE:DHRSartorius AGETR:SR3Merck KGaA (MilliporeSigma)ETR:MRKPCI Pharma ServicesLonza Group AGSWX:LONNFUJIFILM Irvine ScientificCorning IncorporatedNYSE:GLW

Downstream

PANTHERx Specialty PharmacyAlto PharmacyPatient Services, Inc. (PSI)DEB Treatment Centers & Academic Medical CentersMedicare & Medicaid (U.S. Federal & State Payers)Cigna/Express Scripts & Commercial PayersNYSE:CI

Proxies

Sarepta Therapeutics, Inc.NASDAQ:SRPT bluebird bio, Inc.NASDAQ:BLUE BridgeBio Pharma, Inc.NASDAQ:BBIO Vertex Pharmaceuticals IncorporatedNASDAQ:VRTX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Krystal Biotech, Inc.

Key Metrics of KRYS

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of KRYS

Upstream

Downstream

Proxies

Key Metrics of KRYS

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of KRYS

Upstream

Downstream

Proxies